| 000 | 01827 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518052805.0 | ||
| 264 | 0 | _c20201028 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a2045-2322 | ||
| 024 | 7 |
_a10.1038/s41598-019-47630-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchoergenhofer, Christian | |
| 245 | 0 | 0 |
_aDefibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers. _h[electronic resource] |
| 260 |
_bScientific reports _c07 2019 |
||
| 300 |
_a11136 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 |
_aC-Reactive Protein _xmetabolism |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEndotoxemia _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolysin _xmetabolism |
| 650 | 0 | 4 |
_aFibrinolysis _xdrug effects |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLipopolysaccharides _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPolydeoxyribonucleotides _xtherapeutic use |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 |
_aalpha-2-Antiplasmin _xmetabolism |
| 700 | 1 | _aBuchtele, Nina | |
| 700 | 1 | _aGelbenegger, Georg | |
| 700 | 1 | _aDerhaschnig, Ulla | |
| 700 | 1 | _aFirbas, Christa | |
| 700 | 1 | _aKovacevic, Katarina D | |
| 700 | 1 | _aSchwameis, Michael | |
| 700 | 1 | _aWohlfarth, Philipp | |
| 700 | 1 | _aRabitsch, Werner | |
| 700 | 1 | _aJilma, Bernd | |
| 773 | 0 |
_tScientific reports _gvol. 9 _gno. 1 _gp. 11136 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41598-019-47630-6 _zAvailable from publisher's website |
| 999 |
_c29961014 _d29961014 |
||